A new treatment for metastatic pancreatic cancer has shown significant survival gains. The treatment, a multi-selective RAS(ON) inhibitor, has been reported to outperform traditional IV chemotherapy and may potentially double survival rates. Details of the treatment, including its name and specific outcomes, are not consistently reported across sources, but it has generated notable interest and attention at the ASCO 2026 conference.